News release: Clinical study authorised in Sweden for the investigation of CDNF and Renishaw drug delivery system in Parkinson’s patients (docx)

File size: 44 kB Language: English Part number: H-4149-0102

News release:  Clinical study authorised in Sweden for the investigation of CDNF and Renishaw drug delivery system in Parkinson’s patients

The Medicines Agency of Sweden, MPA, has authorised Herantis Pharma Plc and Renishaw plc’s randomised, placebo-controlled Phase 1-2 clinical study, for the investigation of Cerebral Dopamine Neurotrophic Factor (CDNF) and Renishaw’s chronic drug delivery system, in Parkinson’s patients.

This type of file requires a viewer, freely available from Microsoft

Latest videos - Neurological products

Latest items - Neurological products

Didn't find what you were looking for?

Tell us what you couldn’t find and we will do our best to help